- Home
- STWD vs IONS Comparison
STWD vs IONS Comparison
Compare STWD & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STWD
- IONS
- Stock Information
- Founded
- STWD 2009
- IONS 1989
- Country
- STWD United States
- IONS United States
- Employees
- STWD N/A
- IONS N/A
- Industry
- STWD Real Estate Investment Trusts
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- STWD Real Estate
- IONS Health Care
- Exchange
- STWD Nasdaq
- IONS Nasdaq
- Market Cap
- STWD 6.7B
- IONS 5.9B
- IPO Year
- STWD 2009
- IONS 1991
- Fundamental
- Price
- STWD $20.05
- IONS $37.41
- Analyst Decision
- STWD Buy
- IONS Buy
- Analyst Count
- STWD 7
- IONS 18
- Target Price
- STWD $21.83
- IONS $57.59
- AVG Volume (30 Days)
- STWD 2.0M
- IONS 1.5M
- Earning Date
- STWD 08-05-2025
- IONS 07-31-2025
- Dividend Yield
- STWD 9.58%
- IONS N/A
- EPS Growth
- STWD N/A
- IONS N/A
- EPS
- STWD 0.93
- IONS N/A
- Revenue
- STWD $420,478,000.00
- IONS $717,253,000.00
- Revenue This Year
- STWD $349.91
- IONS $7.98
- Revenue Next Year
- STWD $4.33
- IONS $16.09
- P/E Ratio
- STWD $21.48
- IONS N/A
- Revenue Growth
- STWD 7.97
- IONS N/A
- 52 Week Low
- STWD $16.59
- IONS $23.95
- 52 Week High
- STWD $21.17
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- STWD 54.08
- IONS 68.61
- Support Level
- STWD $19.84
- IONS $34.78
- Resistance Level
- STWD $20.24
- IONS $37.54
- Average True Range (ATR)
- STWD 0.27
- IONS 1.06
- MACD
- STWD -0.04
- IONS 0.07
- Stochastic Oscillator
- STWD 56.80
- IONS 95.44
About STWD STARWOOD PROPERTY TRUST INC. Starwood Property Trust Inc.
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment and Investing and Servicing Segment. The company generates the majority of its revenue from the Real estate commercial and residential lending segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.